Talis Biomedical CORP 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Talis Biomedical Corporation has agreed to terminate its Chicago office lease, resulting in a one-time payment of approximately $3.6 million.
Talis Biomedical Corporation has reached a settlement agreement with Kriya Therapeutics, resolving a sublease dispute for $1.9 million and dismissing all related lawsuits.
Talis Biomedical Corporation has amended its previous 8-K filing to clarify that only the company and certain of its current and former directors and officers are defendants in a class action lawsuit settlement, not the underwriters of its IPO.
8-K: Talis Biomedical Reaches $32.5 Million Settlement in Class Action Lawsuit, Plans Chapter 11 Filing
Talis Biomedical Corporation has agreed to a $32.5 million settlement to resolve a securities class action lawsuit, and plans to file for Chapter 11 bankruptcy to implement the settlement.
Talis Biomedical Corporation will be delisted from the Nasdaq Stock Market after suspending all research and development activities and receiving a notice from Nasdaq that it is considered a public shell.
Talis Biomedical Corporation has appointed two new independent directors, formed a special restructuring committee, and initiated steps towards a potential Chapter 11 bankruptcy filing.
Talis Biomedical Corporation has secured a further three-month extension on a waiver of registration rights from Baker Brothers Life Sciences L.P. and 667, L.P., pushing the deadline to September 25, 2024.
Talis Biomedical Corporation has secured a further extension of a waiver on registration rights from Baker Brothers Life Sciences L.P. and 667, L.P. until June 26, 2024.
Talis Biomedical Corporation has extended a waiver agreement with Baker Brothers Life Sciences L.P. and 667, L.P. regarding their registration rights for an additional 30 days, now through May 27, 2024.
Talis Biomedical Corporation has entered into a retention agreement with its Interim Chief Financial Officer, Rebecca Markovich, offering a bonus upon completion of a sale, merger, or liquidation of the company.
Talis Biomedical Corporation eliminated the position of President and Chief Scientific Officer, Dr. Andrew Lukowiak, as part of a strategic restructuring announced in November 2023.